For most of the last two decades, computer system validation in life sciences has been measured by the pound. A validated system meant a binder, and a thick binder meant a defensible one. Somewhere along the way, the industry started confusing the volume of documentation with the quality of the assurance. The FDA's shift toward Computer Software Assurance, articulated in its 2022 draft guidance "Computer Software Assurance for Production and Quality System Software," is an attempt to correct that confusion. It is worth understanding precisely what it moves, because the parts it leaves untouched are exactly the parts teams tend to drop.

What CSA actually changes

CSA is not a new regulation. It is a recommended approach that reinterprets an existing expectation. The predicate requirement, that automated systems used in production and the quality system be validated for their intended use, has not moved. It sits in 21 CFR 820.70(i) for device manufacturers and is echoed across GxP. What CSA changes is where you are expected to spend your effort.

The traditional model, shaped heavily by the 2002 General Principles of Software Validation, encouraged teams to script and document exhaustively, often testing every function to the same depth regardless of its consequence. CSA reframes the goal as critical thinking first, documentation second. It asks you to start from intended use, assess the risk that a given function poses to product quality or patient safety, and then choose an assurance activity proportionate to that risk. A high-risk function that directly affects a batch disposition decision warrants rigorous, scripted testing. A low-risk, vendor-tested feature may be adequately assured through unscripted or ad hoc testing, or by leveraging the supplier's own evidence.

The most quoted line from the guidance is its inversion of effort: less time producing documentation, more time performing the testing and analysis that actually reduces risk. The document explicitly endorses unscripted testing, ad hoc testing, and error-guessing as legitimate assurance activities for appropriate risk levels. That is a meaningful cultural permission slip for an industry that has treated the fully scripted protocol as the only respectable artifact.

What CSA does not change

Here is where teams get into trouble. CSA relaxes the form of your evidence. It does not relax the fact of it.

You still need a record. The guidance is clear that assurance activities must be captured, and that the record should establish what was tested, who performed it, when, and what the result was. Unscripted does not mean undocumented. An error-guessing session that finds a defect still has to produce evidence that the session happened, that the defect was logged, and that it was resolved. The ALCOA+ expectations for that evidence, that it be attributable, legible, contemporaneous, original, and accurate, do not soften because you chose a lighter testing method.

The predicate rules also stand unchanged. 21 CFR Part 11 still governs any electronic record or electronic signature you rely on, whatever assurance approach produced it. EU Annex 11 still applies in Europe regardless of how a US firm labels its methodology. CSA is a way of scoping and executing testing intelligently. It is not a waiver from the underlying record-keeping and integrity obligations, and an inspector will read it that way.

Risk assessment itself becomes more load-bearing, not less. When you decide that a function is low risk and therefore warrants lighter testing, that decision is now the thing you are defending. Under the old model, a reviewer could hide a weak risk rationale behind a mountain of test scripts. Under CSA, the rationale is exposed. If you cannot articulate why a function was scoped the way it was, you have moved effort out of documentation and into a gap.